Klinische Wochenschrift

, Volume 66, Issue 2, pp 43–47

Cyclosporin-associated nephropathy in patients with autoimmune diseases

  • M. J. Mihatsch
  • J. F. Bach
  • H. M. Coovadia
  • Ø. Førre
  • H. M. Moutsopoulos
  • A. A. Drosos
  • K. C. Siamopoulos
  • L. H. Noël
  • R. Ramsaroop
  • R. Hällgren
  • K. Svenson
  • S. O. Bohman
Originalien
  • 14 Downloads

Summary

Renal biopsy specimens were evaluated from patients with different autoimmune diseases treated with cyclosporin (CyA). Ten biopsies were done before CyA, 10 biopsies after low-dose (<7.5 mg/kg/day, initial dose or mean daily dose within the first month, respectively), and 9 after high-dose (>7.5 mg/kg/day) treatment. Definite chronic CyA nephrotoxicity (cyclosporin-associated arteriolopathy and/or interstitial fibrosis striped form with tubular atrophy) was only present in the initial high-dose group. In this group a significant serum creatinine increase was noted and 8 of the 9 patients were hypertensive. No significant correlation was found between the severity of morphologic lesions and the mean daily dose during total treatment, cumulative dose, and duration of therapy. The morphologic changes in the low-dose group did not differ from the control biopsy specimens before CyA treatment. Based on these results, it can be concluded that major nephrotoxicity can be avoided by initial low CyA doses.

Key words

Cyclosporin Nephropathy Side effects Autoimmune disease 

Abbreviations

CyA

Cyclosporin A

NSAID

Nonsteroidal antiinflammatory drugs

SLE

Systemic lupus erythematosus

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bergstrand A, Bohman SO, Farnsworth A (1985) Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A. Clin Nephrol 24:107–119Google Scholar
  2. 2.
    Boitnott JK, Solez K (1984) The use of ranking in the statistical assessment of morphological data. In: Solez K, Whelton A (eds) Acute renal failure. Marcel Dekker, New York, Basle, pp 13–16Google Scholar
  3. 3.
    Farnsworth A, Hall BM, Ng ABP (1984) Renal biopsy morphology in renal transplantation. A comparative study of the light microscopic appearances of biopsies from patients treated with Cyclosporin A or azathioprine, prednisone and antilymphocyte globulin. Am J Surg Pathol 8:243–252Google Scholar
  4. 4.
    Feutren G, Querin S, Chatenoud L, Noël LH, Beaurain G, Lesavre P, Bach JF (1985) The effects of cyclosporin in twelve patients with severe systemic lupus. In: Schindler R (ed) Cyclosporin in autoimmune diseases. 1st Internationale Symposium, Basle. Springer, Berlin, Heidelberg, New York, pp 367–372Google Scholar
  5. 5.
    von Graffenried B, Harrison WB (1985) Renal function in patients with autoimmune disease treated with cyclosporin. Transplant Proc [Suppl 1] 17:215–131Google Scholar
  6. 6.
    Klintmalm G, Ringden O, Groth CG (1983) Clinical and laboratory signs in nephrotoxicity and rejection in cyclosporin-treated renal allograft recipients. Transplant Proc 15:2815–2820Google Scholar
  7. 7.
    Klintmalm G, Bohman SO, Sundelin B, Wilczek H (1984) Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low-doses in early post-transplantation period. Lancet II:950–953Google Scholar
  8. 8.
    Krupp P, Timonen O, Gülich A (1985) Side effects and safety of sandimmun in long-term treatment of transplant patients. In: Schindler R (ed) Cyclosporin in autoimmune disease. 1st International Symposium, Basle. Springer, Berlin, Heidelberg, New York, pp 43–49Google Scholar
  9. 9.
    Mihatsch MJ, Thiel G, Spichtin HP (1983) Morphological findings in kidney transplants after treatment with cyclosporin. Transplant Proc 15:2821–2835Google Scholar
  10. 10.
    Mihatsch MJ, Thiel G, Basler V (1985) Morphological paterns in cyclosporin-treated renal transplant recipients. Transpl Proc [Suppl 1] 17:101–116Google Scholar
  11. 11.
    Mihatsch MJ, Thiel G, Ryffel B (1985) Cyclosporin-associated nephropathy. In: Schindler R (ed) Cyclosporin in autoimmune diseases. 1st International Symposium, Basle. Springer, Berlin, Heidelberg, New York, pp 50–58Google Scholar
  12. 12.
    Myers BD, Ross J, Newton L (1984) Cyclosporin-associated chronic nephropathy. N Engl J Med 311:699–705Google Scholar
  13. 13.
    Palestine AG, Austin HA, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB, (1986) Renal histopathologic alterations in patients treated with cyclosporin for uveitis. N Engl J Med 314:1293–1298Google Scholar
  14. 14.
    Sibley RK, Ferguson RM, Sutherland DER (1983) Morphology of cyclosporin nephrotoxicity and of acute rejection in cyclosporin-prednisone immunosuppressed renal allograft recipients. Transplant Proc 15:2836–2841Google Scholar
  15. 15.
    Svenson K, Bohman SO Hallgren R (1985) Clinical effects and renal side effects in patients with autoimmune diseases treated with cyclosporin. In: Schindler R (ed) Cyclosporin in autoimmune diseases. 1st International Symposium, Basle. Springer, Berlin, Heidelberg, New York, pp 74–79Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • M. J. Mihatsch
    • 1
  • J. F. Bach
    • 2
  • H. M. Coovadia
    • 3
  • Ø. Førre
    • 4
  • H. M. Moutsopoulos
    • 5
  • A. A. Drosos
    • 5
  • K. C. Siamopoulos
    • 5
  • L. H. Noël
    • 2
  • R. Ramsaroop
    • 3
  • R. Hällgren
    • 6
  • K. Svenson
    • 6
  • S. O. Bohman
    • 7
  1. 1.Institut für PathologieUniversität BaselSwitzerland
  2. 2.Service d'Immunologie CliniqueHôpital NeckerParisFrance
  3. 3.Department of PaediatricsUniversity of Natal and King Edward VIII HospitalDurbanSouth Africa
  4. 4.Oslo AnitetsforeningsRheumatism HospitalOsloNorway
  5. 5.Department of MedicineUniversity of IoanninaIoanninaGreece
  6. 6.Dept. Int. Medicine, Section of RheumatologyUniversity HospitalUppsalaSweden
  7. 7.Department of Pathology, Karolinska InstituteHuddinge HospitalHuddingeSweden

Personalised recommendations